Cargando…
Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association for the Study of the Liver
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013613/ https://www.ncbi.nlm.nih.gov/pubmed/35164434 http://dx.doi.org/10.3350/cmh.2022.0040 |
| _version_ | 1784688031646613504 |
|---|---|
| author | Takamura, Saori Teraki, Yuichi Katayama, Eri Kawaguchi, Takumi Kawaguchi, Machiko Nakano, Dan Tsutsumi, Tsubasa Nagoshi, Sumiko Nakama, Takekuni Torimura, Takuji |
| author_facet | Takamura, Saori Teraki, Yuichi Katayama, Eri Kawaguchi, Takumi Kawaguchi, Machiko Nakano, Dan Tsutsumi, Tsubasa Nagoshi, Sumiko Nakama, Takekuni Torimura, Takuji |
| author_sort | Takamura, Saori |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9013613 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The Korean Association for the Study of the Liver |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90136132022-04-26 Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs Takamura, Saori Teraki, Yuichi Katayama, Eri Kawaguchi, Takumi Kawaguchi, Machiko Nakano, Dan Tsutsumi, Tsubasa Nagoshi, Sumiko Nakama, Takekuni Torimura, Takuji Clin Mol Hepatol Letter to the Editor The Korean Association for the Study of the Liver 2022-04 2022-02-15 /pmc/articles/PMC9013613/ /pubmed/35164434 http://dx.doi.org/10.3350/cmh.2022.0040 Text en Copyright © 2022 by The Korean Association for the Study of the Liver https://creativecommons.org/licenses/by-nc/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Takamura, Saori Teraki, Yuichi Katayama, Eri Kawaguchi, Takumi Kawaguchi, Machiko Nakano, Dan Tsutsumi, Tsubasa Nagoshi, Sumiko Nakama, Takekuni Torimura, Takuji Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs |
| title | Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs |
| title_full | Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs |
| title_fullStr | Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs |
| title_full_unstemmed | Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs |
| title_short | Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs |
| title_sort | effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: directed acyclic graphs |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9013613/ https://www.ncbi.nlm.nih.gov/pubmed/35164434 http://dx.doi.org/10.3350/cmh.2022.0040 |
| work_keys_str_mv | AT takamurasaori effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT terakiyuichi effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT katayamaeri effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT kawaguchitakumi effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT kawaguchimachiko effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT nakanodan effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT tsutsumitsubasa effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT nagoshisumiko effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT nakamatakekuni effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs AT torimuratakuji effectsofinterleukin17inhibitorsonhepaticfibrosisindexinpatientswithpsoriasisandmetabolicdysfunctionassociatedfattyliverdiseasedirectedacyclicgraphs |